Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group
- PMID: 9454659
- DOI: 10.1006/gyno.1997.4887
Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group
Abstract
Objective: The objective of this study was to study the effectiveness of cyclosporin A and cisplatin in patients with recurrent epithelial ovarian cancer. METHODS. Twenty-six patients with measurable recurrent epithelial ovarian cancer, considered to be resistant to cisplatin, received cisplatin in combination with cyclosporin A. Patients received 75 mg/m2 cisplatin every 3 weeks and two cyclosporin A injections over 2 h each, 24 h apart, at a dose of 4 mg/kg each.
Results: Only a single patient had a complete response, with two experiencing a partial response to cyclosporin A/cisplatin combination. Hematologic toxicity in this study was modest. No patient developed grade 4 renal toxicity.
Conclusion: These data indicate minimal activity of the combination of cyclosporin A and cisplatin in ovarian cancer patients with recurrent measurable disease previously treated with cisplatin and thought to be resistant to this chemotherapeutic agent.
Copyright 1998 Academic Press.
Similar articles
-
A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.Gynecol Oncol. 2006 Mar;100(3):586-90. doi: 10.1016/j.ygyno.2005.09.032. Epub 2005 Oct 24. Gynecol Oncol. 2006. PMID: 16249022 Clinical Trial.
-
Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.Clin Cancer Res. 1996 Oct;2(10):1693-7. Clin Cancer Res. 1996. PMID: 9816118 Clinical Trial.
-
Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.Clin Cancer Res. 1996 Oct;2(10):1699-704. Clin Cancer Res. 1996. PMID: 9816119 Clinical Trial.
-
Medical therapy of advanced malignant epithelial tumours of the ovary.Forum (Genova). 2000 Oct-Dec;10(4):323-32. Forum (Genova). 2000. PMID: 11535983 Review.
-
Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.J Natl Compr Canc Netw. 2004 Sep;2 Suppl 2:S60-73. J Natl Compr Canc Netw. 2004. PMID: 19780247 Review.
Cited by
-
Clinical perspectives on platinum resistance.Drugs. 2000;59 Suppl 4:9-17; discussion 37-8. doi: 10.2165/00003495-200059004-00002. Drugs. 2000. PMID: 10864226 Review.
-
NFATC4 promotes quiescence and chemotherapy resistance in ovarian cancer.JCI Insight. 2020 Apr 9;5(7):e131486. doi: 10.1172/jci.insight.131486. JCI Insight. 2020. PMID: 32182216 Free PMC article.
-
Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies.Neoplasia. 1999 Jun;1(2):118-22. doi: 10.1038/sj.neo.7900019. Neoplasia. 1999. PMID: 10933045 Free PMC article.
-
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.Gynecol Oncol. 2011 Oct;123(1):19-26. doi: 10.1016/j.ygyno.2011.06.022. Epub 2011 Jul 12. Gynecol Oncol. 2011. PMID: 21752435 Free PMC article. Clinical Trial.
-
Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.J Clin Oncol. 2009 Jun 1;27(16):2686-91. doi: 10.1200/JCO.2008.19.2963. Epub 2009 Mar 30. J Clin Oncol. 2009. PMID: 19332726 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
